Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (111-120 of 311) with videos related to

Pageof 32
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|June 10, 2008
HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?Christian Widakowich, Phuong Dinh, Evandro de Azambuja, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2024
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancerFrançois Cherifi, Angélique Da Silva, Diogo Martins-Branco, et al.
European Journal of Case Reports in Internal Medicine|March 26, 2021
Sarcoidosis Versus Lymphoma?Lissandra Dal Lago, Julie Sarrand, Erwin Woff, et al.
Clinical Breast Cancer|May 14, 2023
Corrigendum to "Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer" [Clin Breast Cancer 2020; 20:262-73.e7]Rafael Caparica, François Richard, Mariana Brandão, et al.
Clinical Breast Cancer|April 2, 2020
Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast CancerRafael Caparica, François Richard, Mariana Brandão, et al.
Cancers|April 30, 2021
RTK Inhibitors in Melanoma: From Bench to BedsideMalak Sabbah, Ahmad Najem, Mohammad Krayem, et al.
Anti-Cancer Drugs|October 15, 2019
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patientFadi Farhat, Mohammad Tarabaih, Ali Kanj, et al.
International Journal of Oncology|November 22, 2024
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profilesPhilippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, et al.
Anti-Cancer Drugs|November 1, 2006
Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalpBernd Kasper, Dominique Lossignol, Thierry Gil, et al.
Journal of Geriatric Oncology|June 8, 2019
Targeted therapy for breast cancer in older patientsNoam Pondé, Hans Wildiers, Ahmad Awada, et al.
Pageof 32

Showing results (111-120 of 311) with videos related to

Sort By:
Pageof 32
Anti-Cancer Agents in Medicinal Chemistry|June 10, 2008
HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?Christian Widakowich, Phuong Dinh, Evandro de Azambuja, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2024
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancerFrançois Cherifi, Angélique Da Silva, Diogo Martins-Branco, et al.
European Journal of Case Reports in Internal Medicine|March 26, 2021
Sarcoidosis Versus Lymphoma?Lissandra Dal Lago, Julie Sarrand, Erwin Woff, et al.
Clinical Breast Cancer|May 14, 2023
Corrigendum to "Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer" [Clin Breast Cancer 2020; 20:262-73.e7]Rafael Caparica, François Richard, Mariana Brandão, et al.
Clinical Breast Cancer|April 2, 2020
Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast CancerRafael Caparica, François Richard, Mariana Brandão, et al.
Cancers|April 30, 2021
RTK Inhibitors in Melanoma: From Bench to BedsideMalak Sabbah, Ahmad Najem, Mohammad Krayem, et al.
Anti-Cancer Drugs|October 15, 2019
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patientFadi Farhat, Mohammad Tarabaih, Ali Kanj, et al.
International Journal of Oncology|November 22, 2024
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profilesPhilippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, et al.
Anti-Cancer Drugs|November 1, 2006
Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalpBernd Kasper, Dominique Lossignol, Thierry Gil, et al.
Journal of Geriatric Oncology|June 8, 2019
Targeted therapy for breast cancer in older patientsNoam Pondé, Hans Wildiers, Ahmad Awada, et al.
Pageof 32